Abbisko Therapeutics’ Oral Small Molecule KRAS G12D Inhibitor Approved for Clinical Trials in the US
December 3, 2025
Source: drugdu
50
Abbisko Therapeutics announced that its investigational oral, highly active, highly selective small molecule KRAS G12D inhibitor, ABSK141, has received approval from the US Food and Drug Administration (FDA) for an Investigational New Drug (IND) application to treat patients with advanced solid tumors harboring the KRAS G12D mutation.
Commentary: The announcement by Abbisko Therapeutics that its oral KRAS G12D inhibitor ABSK141 has received FDA IND approval is a critical R&D advancement. This drug targets the KRAS G12D mutation, for which there are currently no approved targeted therapies. This mutation is one of the most common oncogenic mutations in various solid tumors, including pancreatic and colorectal cancers, highlighting a pressing clinical need.
https://finance.eastmoney.com/a/202512033580752973.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
